Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | SLC5A2 | P31639 | 13/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25608169 | 0.84 | SLC5A2 (0.53) | SLC5A2 | |
| SCHEMBL23547951 | 0.82 | TSHR (0.39) | OGATSHRSLC5A2EPHX1 | |
| SCHEMBL23547696 | 0.82 | TSHR (0.39) | OGATSHRSLC5A2EPHX1 | |
| SCHEMBL26554489 | 0.81 | TSHR (0.36) | TSHREPHX1 | |
| SCHEMBL50998 | 0.77 | TSHR (0.43) | TSHREPHX1 | |
| SCHEMBL7951294 | 0.77 | TSHR (0.43) | TSHREPHX1 | |
| SCHEMBL12582963 | 0.77 | OGA (0.37) | OGASLC5A2 | |
| SCHEMBL15298424 | 0.76 | SLC5A2 (0.44) | TSHRSLC5A2 | |
| SCHEMBL25605619 | 0.75 | EPHX1 (0.40) | OGAEPHX1 | |
| SCHEMBL25676495 | 0.73 | LGALS3 (0.39) | OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365970-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230332153-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365970-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | NSUN2, SNRPA, SNRPF | OGA 128/4885TSHR 2910/4885SLC5A2 2758/4885 |
| US-20230332153-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | NSUN2, SNRPA, SNRPF | OGA 128/4885TSHR 2910/4885SLC5A2 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.